Xtandi, the only Astellas drug tracked here, made ≈$6.0B of its 2025 revenue (45%) and loses US exclusivity in 2027. Since 2023, Astellas has closed 1 acquisition of $1B or more, worth $5.9B. Products from that deal brought in $488M in 2025.
Bars are each drug's 2025 sales as a share of Astellas’ total revenue (≈$13.4B). Total revenue ¥2,139.2B, fiscal year to March 2026. Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Jul 2023 | Iveric BioAstellas, July 2023 | $5.9B | Other | Izervay for geographic atrophy, an eye disease, approved by the FDA in August 2023, after the deal closed2025 sales: Izervay $488M. Converted from ¥77.6B at the rate used for Astellas revenue; fiscal year April 2025 to March 2026. Astellas FY2025 earnings call | Pipeline only |
| 1 counted | $5.9B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Astellas announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | ≈$6.0B | – |
| Other | – | $5.9B |
Astellas has the most revenue at risk in oncology, but has spent the most on acquisitions outside the main areas (Iveric Bio). At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Astellas paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. The closest like-for-like figure is sales of the products Astellas bought: $488M in 2025, against ≈$6.0B of 2025 sales losing US exclusivity by 2037. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: Astellas FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Astellas’ announcement or filing in the table above.
See all 45 drugs on the patent cliff →